

New commercial chief at Ra Pharma

19 April 2018 | News | By Priyanka Bajpai

Mr. King brings to Ra Pharma more than 20 years of senior, global, commercial leadership experience within the biotechnology rare disease space, most recently with Alexion Pharmaceuticals.



Singapore- Ra Pharmaceuticals, a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for the treatment of complement-mediated diseases, announced the appointment of John C. King as Chief Commercial Officer, effective April 16, 2018. Mr. King brings to Ra Pharma more than 20 years of senior, global, commercial leadership experience within the biotechnology rare disease space, most recently with Alexion Pharmaceuticals.

“Having led the successful launch and commercialization of Soliris for generalized myasthenia gravis (gMG) in the U.S. and growth of paroxysmal nocturnal hemoglobinuria (PNH) in markets around the world, John is ideally suited to help us build the commercial foundation for RA101495 SC in complement-mediated diseases,” said Doug Treco, PhD, President and Chief Executive Officer of Ra Pharma. “With enrollment in our Phase II trial of RA101495 SC in gMG progressing rapidly, and continued advancement of our PNH program, we look forward to John’s contributions to the leadership team.”